Lyra Therapeutics Résultats passés
Passé contrôle des critères 0/6
Lyra Therapeutics's earnings have been declining at an average annual rate of -34.1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 51.7% per year.
Informations clés
-34.1%
Taux de croissance des bénéfices
92.5%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 6.0% |
Taux de croissance des recettes | 51.7% |
Rendement des fonds propres | -327.3% |
Marge nette | -5,570.9% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?
Mar 05Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth
Jan 11Lyra Therapeutics down 19% underwhelming data from lead program
Dec 07Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis
Nov 24Ventilation des recettes et des dépenses
Comment Lyra Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 2 | -101 | 20 | 0 |
31 Mar 24 | 2 | -69 | 20 | 0 |
31 Dec 23 | 2 | -63 | 19 | 0 |
30 Sep 23 | 1 | -62 | 19 | 0 |
30 Jun 23 | 1 | -61 | 17 | 0 |
31 Mar 23 | 1 | -60 | 18 | 0 |
31 Dec 22 | 1 | -55 | 18 | 0 |
30 Sep 22 | 2 | -55 | 18 | 0 |
30 Jun 22 | 1 | -51 | 17 | 0 |
31 Mar 22 | 1 | -48 | 16 | 0 |
31 Dec 21 | 0 | -44 | 14 | 0 |
30 Sep 21 | 0 | -37 | 16 | 0 |
30 Jun 21 | 0 | -32 | 14 | -5 |
31 Mar 21 | 0 | -26 | 11 | -3 |
31 Dec 20 | 0 | -22 | 10 | 0 |
30 Sep 20 | 0 | -20 | 8 | 3 |
30 Jun 20 | 0 | -18 | 6 | 11 |
31 Mar 20 | 0 | -17 | 5 | 12 |
31 Dec 19 | 0 | -17 | 4 | 12 |
31 Dec 18 | 1 | -6 | 4 | 5 |
Des revenus de qualité: LYRA is currently unprofitable.
Augmentation de la marge bénéficiaire: LYRA is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: LYRA is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.
Accélération de la croissance: Unable to compare LYRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: LYRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement des fonds propres
ROE élevé: LYRA has a negative Return on Equity (-327.31%), as it is currently unprofitable.